Last edition
News about "Dominik Ruettinger"
Bayer Initiates Phase 2 Trial of Investigational GIRK4 Inhibitor for Atrial Fibrillation
Bayer has initiated a global Phase 2 trial of BAY 3670549, an investigational GIRK4 inhibitor being evaluated as a potential treatment for atrial fibrillation and rapid cardioversion.
Dominik Ruettinger | 10/09/2026 | By News Bureau
Bayer and Kumquat Biosciences have begun a Phase-I trial of their KRAS G12D inhibitor targeting KRAS-mutated tumors, further bolstering Bayer’s precision oncology pipeline across pancreatic, colorectal, and lung cancers.
Dominik Ruettinger | 11/10/2025 | By Dineshwori | 1174
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy